Brought to you by 
Juno closes $134mm Series B round
06 Aug 2014
Executive Summary
Juno Therapeutics Inc. (cancer immunotherapies) closed its second huge financing in less than 12 months. The company raised $134mm through its Series B round from all existing major investors (Arch Venture Partners and Crestline Investors were key Series A participants) as well as ten public mutual funds and health care-focused funds. Juno's Series A round closed in April bringing in a whopping $176mm; proceeds from both financings are funding Juno's pipeline of chimeric antigen receptor and T-cell receptor therapies.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Juno closes $134mm Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice